An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation

Inflammation Research

Volumn 51, Issue 4, 2002, Pages 188-194

  Aikawa, Y ^a   Yamamoto, M ^a   Yamamoto, T ^a   Morimoto, K ^a   Tanaka, K ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Anti rheumatic agent; Cytokines; I B ; NF B; T 614

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; DIGOXIGENIN; DNA; I KAPPA B ALPHA; IGURATIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MONOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 0036234632     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000291     Document Type: Article

References (40)

1. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopy-ran-4-one: 1st communication: Antiinflammatory, analgesic and other related properties
2. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones: Antiarthritic effect of the formylamino compound (T-614) in chronic inflammatory disease models
3. Pharmacological studies of T-614, a novel antiinflammatory agent: Effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/1 mice
4. Pharmacological studies on 3-formylamino-7-methylsulfonyl-amino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. Inhibitory effect on the production of interleukin-1 and interleukin-6
5. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis
6. Inhibitory effect of a new anti-rheumatic drug T-614 in costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells
7. Activation of interleukin-6 gene expression through the NF-κB transcription factor
8. Establishment of lipopolysaccharide-dependent nuclear factor κB activation in a cell-free system
9. Microbial superantigens induce NF-κB in the human monocytic cell line THP-1
10. Membrane molecules which trigger the production of interleukin-1 and tumor necrosis factor-α by lipopolysaccharide-stimulated human monocytes
11. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes
12. κ B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages
13. Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8
14. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes
15. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8
16. Triggering of the human interleukin-6 gene by interferon-γ and tumor necrosis factor-α in monocytic cells involves cooperation between interferon regulatory factor-1, NFκB, and Sp1 transcription factors
17. Cooperative interaction of nuclear factor-κB- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines
18. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor κB and CCAAT/enhancer-binding protein-like cis-elements
19. Tumor necrosis factor-α and interferon γ synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-κB-like binding sites of the interleukin 8 gene
20. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
21. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
22. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor
23. Suppression of NF-κB activation and NF-κB-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase
24. Extension of the life-span of human endothelial cells by an interleukin-1 α antisense oligomer
25. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells
26. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
27. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, I-κB-α
28. Signal transduction through NF-κB
29. NF-κB: A key role in inflammatory diseases
30. The transcription factor NF-κB and human disease
31. Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity
32. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane)
33. Inhibition of NF-κB by sodium salicylate and aspirin
34. Sanguinarine (pseudocheylerythrine) is a potent inhibitor of NF-κB activation, IκBα phosphorylation, and degradation
35. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes
36. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB
37. An essential role for NF-κB in preventing TNF-α-induced cell death
38. Inhibition of T cell apoptosis in the rheumatoid synovium
39. Caffeic acid phenethyl ester induces leukocyte apoptosis, modulate nuclear factor-κB and suppress acute inflammation
40. Inhibition of nuclear factor-κB and induction of apoptosis in T-lymphocytes by sulfasalazine